Fenofibrate reduces cisplatin-induced apoptosis by inhibiting the p53/Puma/Caspase-9 pathway and the MAPK/Caspase-8 pathway rather than by promoting autophagy in murine renal proximal tubular cells.

Apoptosis Autophagy Cisplatin Fenofibrate Mitochondrial and death receptor pathways Renal tubular cells

Journal

Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 24 11 2021
revised: 12 02 2022
accepted: 17 02 2022
entrez: 7 3 2022
pubmed: 8 3 2022
medline: 8 3 2022
Statut: epublish

Résumé

The main lesion of cisplatin nephrotoxicity is damage to proximal tubular cells due to increased apoptosis via the mitochondrial and death receptor pathways, which may be alleviated by appropriate promotion of autophagy. Fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPAR-α) activator, is recently reported to promote autophagy as well as protect against cisplatin nephrotoxicity, although the mechanisms were only partially analyzed. Here, the detailed mechanisms of these putative protective effects were investigated in a murine renal proximal tubular (mProx) cell line. Fenofibrate attenuated cisplatin-induced apoptosis of mProx cells based on flow cytometry. As for the mitochondrial apoptotic pathway, the reagent reduced cisplatin-stimulated caspase-3 activation by decreasing the phosphorylation of p53, JNK, and 14-3-3, cytosolic and mitochondrial Puma accumulation, cytochrome C release to the cytosol, and resulting cytosolic caspase-9 activation. Fenofibrate also decreased cisplatin-stimulated activation of caspases-8 by suppressing MAPK and NFkB pathways and reducing the gene expression of TNF-α, TL1A, and Fas, main mediators of the death receptor apoptotic pathway. Autophagy defined by p62 reduction and an increase in LC3 II/I was promoted by fenofibrate in mProx cells under starvation. Autophagy inhibition using 3-MA further increased basal and cisplatin-induced caspase-3 and -8 activation, but had no influence on the inhibitory effects of fenofibrate on caspase activation. In conclusion, our study suggests fenofibrate to be a candidate agent to mitigate cisplatin nephrotoxicity by inhibiting the mitochondrial and death apoptotic pathways rather than by promoting autophagy.

Identifiants

pubmed: 35252595
doi: 10.1016/j.bbrep.2022.101237
pii: S2405-5808(22)00037-1
pmc: PMC8889369
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101237

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work in this paper.

Références

Cell. 1996 Nov 15;87(4):619-28
pubmed: 8929531
Am J Physiol Renal Physiol. 2008 Apr;294(4):F777-87
pubmed: 18256309
Mol Cell. 2008 Jun 20;30(6):678-88
pubmed: 18570871
Am J Physiol Renal Physiol. 2005 Aug;289(2):F469-80
pubmed: 15814532
Int J Mol Sci. 2015 Dec 18;16(12):30321-41
pubmed: 26694384
Kidney Int. 2001 Jul;60(1):14-30
pubmed: 11422732
Kidney Int. 2017 Apr;91(4):880-895
pubmed: 28040265
Biochem Biophys Res Commun. 2014 Nov 14;454(2):320-7
pubmed: 25450396
Clin Exp Nephrol. 2021 Jun;25(6):598-607
pubmed: 33646450
Electrolyte Blood Press. 2014 Dec;12(2):55-65
pubmed: 25606044
Sci Rep. 2016 Apr 07;6:23975
pubmed: 27052588
J Am Soc Nephrol. 2002 Apr;13(4):858-865
pubmed: 11912244
J Toxicol Sci. 2016;41(3):339-49
pubmed: 27193727
Kidney Int. 2005 Dec;68(6):2680-93
pubmed: 16316343
Nature. 2014 Dec 4;516(7529):112-5
pubmed: 25383539
Am J Physiol Renal Physiol. 2017 Feb 1;312(2):F323-F334
pubmed: 27465995
J Am Soc Nephrol. 2014 Oct;25(10):2278-89
pubmed: 24700871
Kidney Int. 2007 Jul;72(1):53-62
pubmed: 17410096
Crit Care Med. 2009 Jun;37(6):2033-44
pubmed: 19384198
Oncogene. 2008 Dec;27 Suppl 1:S71-83
pubmed: 19641508
Kidney Int. 2016 Apr;89(4):779-91
pubmed: 26924060
Am J Pathol. 2012 Feb;180(2):517-25
pubmed: 22265049
Kidney Int. 2012 Dec;82(12):1271-83
pubmed: 22854643
Am J Pathol. 2006 Mar;168(3):737-47
pubmed: 16507889
Biomed Res Int. 2014;2014:967826
pubmed: 25165721

Auteurs

Hideki Kimura (H)

Department of Clinical Laboratory, University of Fukui Hospital, Fukui, Japan.

Kazuko Kamiyama (K)

Department of Clinical Laboratory, University of Fukui Hospital, Fukui, Japan.

Toru Imamoto (T)

Department of Clinical Laboratory, University of Fukui Hospital, Fukui, Japan.

Izumi Takeda (I)

Department of Clinical Laboratory, University of Fukui Hospital, Fukui, Japan.

Shinya Masunaga (S)

Department of Clinical Laboratory, University of Fukui Hospital, Fukui, Japan.

Mamiko Kobayashi (M)

Division of Nephrology, Department of General Medicine, School of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Daisuke Mikami (D)

Division of Nephrology, Department of General Medicine, School of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Naoki Takahashi (N)

Division of Nephrology, Department of General Medicine, School of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Kenji Kasuno (K)

Division of Nephrology, Department of General Medicine, School of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Takeshi Sugaya (T)

Cimic Corporation, Tokyo, Japan.

Masayuki Iwano (M)

Division of Nephrology, Department of General Medicine, School of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Classifications MeSH